Compare · COO vs RXST
COO vs RXST
Side-by-side comparison of The Cooper Companies Inc. (COO) and RxSight Inc. (RXST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COO and RXST operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- COO is the larger of the two at $19.03B, about 62.1x RXST ($306.3M).
- Over the past year, COO is down 24.2% and RXST is down 53.3% - COO leads by 29.1 points.
- COO has been more active in the news (14 items in the past 4 weeks vs 6 for RXST).
- Both have 25 recent analyst ratings on file.
- Company
- The Cooper Companies Inc.
- RxSight Inc.
- Price
- $62.37-0.83%
- $7.41+4.74%
- Market cap
- $19.03B
- $306.3M
- 1M return
- -12.68%
- +17.17%
- 1Y return
- -24.22%
- -53.28%
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 14
- 6
- Recent ratings
- 25
- 25
The Cooper Companies Inc.
The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through two segments, CooperVision and CooperSurgical. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia. It also provides range of products and services for enhancing health of women, babies, and families, including medical devices, fertility, genomics, and diagnostics and contraception for hospitals and surgical centers, obstetricians' and gynecologists' (OB/GYNs) medical offices, and fertility clinics. In addition, the company develops mechanical surgical solutions for skin closure; and offers PARAGARD, a contraceptive, as well as provides assisted reproductive technology products, genetic screening and testing, and products within the general OB/GYN offerings. It markets its products under Biofinity, clariti 1day, MyDay, Avaira Vitality, and Proclear 1 Day brand name through a network of field sales representatives, independent agents, eye care practitioners, and distributors. The Cooper Companies, Inc. was founded in 1980 and is headquartered in San Ramon, California.
RxSight Inc.
RxSight, Inc., a medical technology company, develops light adjustable lens (LAL) to improve uncorrected visual acuity that can be adjusted enhance uncorrected visual acuity after cataract surgery. It also offers RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is based in Aliso Viejo, California.
Latest COO
- CooperCompanies Announces Release Date for Second Quarter 2026
- SEC Form 4 filed by Rosebrough Walter M Jr
- CooperVision Partners with Canadian Olympic Speed Skater Valérie Maltais on Her Continued Pursuit of Excellence on the World Stage
- CooperVision Launches MADE BETTER™ Promise Beginning with MyDay® Contact Lenses*¹
- Telix Strengthens Board with Additional Director Appointments
- The Cooper Companies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Weiss Robert S
- SEC Form 4 filed by Rivas Maria
- SEC Form 4 filed by Jay Colleen
- SEC Form 4 filed by Carbone Barbara
Latest RXST
- RxSight, Inc. to Present at the Bank of America Healthcare Conference
- SEC Form DEFA14A filed by RxSight Inc.
- SEC Form DEF 14A filed by RxSight Inc.
- RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6
- SEC Form 4 filed by Goldshleger Ilya
- RxSight Highlights 300,000 Light Adjustable Lens Implant Milestone and Strong Scientific Presence at ASCRS 2026
- RxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by RxSight Inc.
- Amendment: SEC Form 8-K/A filed by RxSight Inc.
- Chief Financial Officer Wilterding Mark converted options into 20,441 shares and covered exercise/tax liability with 8,068 shares (SEC Form 4)